This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Oncology drug development is no longer a singles market as ...

Pembrolizumab combined with weekly paclitaxel ± bevacizumab reduced death risk by 18% and improved median OS by 3.7 months versus paclitaxel ± bevacizumab in all comers. Progression-free survival ...

Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company’s ...

Event-free survival improved with EV/pembro: median not reached vs 48.5 months, and 24‑month EFS 79.4% vs 66.2% with cisplatin/gemcitabine. Overall survival separated early (24‑month 86.9% vs 81.3%), ...

The combination of Padcev and Keytruda has once again delivered strong results, this time significantly improving overall survival (OS) for patients with cisplatin-eligible muscle-invasive bladder ...

Merck said on Monday it would split its business into two, creating ⁠a distinct division for its cancer franchise led by blockbuster drug Keytruda while grouping its non-oncology treatments separately ...

Merck MRK0.38%increase; green up pointing triangle is shaking up the leadership of its main pharmaceutical unit as the U.S. drugmaker braces for sales pressure later this decade. The Rahway, ...

Merck & Co. is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its best-selling cancer ...

Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster cancer drug Keytruda for certain patients with ...

(Reuters) Merck said on Monday it would create a separate division for its cancer business, anchored by its top-selling drug Keytruda, as the U.S. drugmaker braces for the upcoming patent expiry of ...

Feb 23 (Reuters) - Merck said on Monday it would split its human-health business into two units, creating a division for its cancer franchise led by blockbuster drug Keytruda while grouping its ...